N-Terminal Pro-B-Type Natriuretic Peptide Post-Discharge Monitoring in the Management of Patients with Heart Failure and Preserved Ejection Fraction – A Randomized Trial: The NICE Study
European Journal of Heart Failure · 2024
DOI: 10.1002/ejhf.3222 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Domingo A Pascual-Figal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Virgen de la Arrixaca, Universidad de Murcia, IMIB-Pascual Parrilla, Murcia, Spain. Hauptthemen laut MEDLINE: Heart Failure, Natriuretic Peptide, Brain, Peptide Fragments, Stroke Volume. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Roche España.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
There is a lack of specific studies assessing the impact of natriuretic peptide monitoring in the post-discharge management of patients with heart failure (HF) and preserved ejection fraction (HFpEF), throughout the vulnerable phase following acute HF hospitalization. The NICE study aims to assess the clinical benefit of incorporating N-terminal pro-B-type natriuretic peptide (NT-proBNP) into the post-discharge management of HFpEF patients. Methods and results Individuals admitted with HFpEF (left ventricular ejection fraction >50%) were included in a multicentre randomized controlled study employing an open-label design with event blinding (NCT02807168). Upon discharge, 157 patients were randomly allocated to either NT-proBNP monitoring (n = 79) or no access to NT-proBNP (control group, n = 78) during pre-scheduled visits at 2, 4 and 12 weeks. Clinical endpoints were evaluated at 6 months. The primary endpoint of HF rehospitalizations occurred in 12.1% patients, without significant differences observed between the NT-proBNP monitoring group (12.8%) and the control group (11.4%) (hazard ratio [HR] 1.15, 95% confidence interval [CI] 0.47–2.81, p = 0.760). Regarding secondary endpoints, the NT-proBNP monitoring group demonstrated a significantly lower risk of death (1.3% vs. 10.1%; HR 0.12, 95% CI 0.02–0.98; p = 0.048), whereas non-HF hospitalizations (12.8% vs. 19.0%, p = 0.171) and any adverse clinical event (26.9% vs. 36.7%, p = 0.17) did not reach statistical significance [Correction added on 29 April 2024, after first online publication: In the preceding sentence, “95% CI 0.02 - 0.09” has been corrected to “95% CI 0.02 - 0.98; p = 0.048” in this version.]. Awareness of NT-proBNP levels were associated with higher doses of diuretics and renin–angiotensin system inhibitors (angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers) in the NT-proBNP monitoring group.
Conclusions
Post-discharge monitoring of NT-proBNP in HFpEF patients did not exhibit an association with reduced rates of HF hospitalization in this study. Nonetheless, it appears to enhance global clinical management by optimizing medical therapies and contributing to improved overall survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Virgen de la Arrixaca, Universidad de Murcia, IMIB-Pascual Parrilla, Murcia, Spain.
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
- CIBERCV, Madrid, Spain.
- Hospital Gregorio Marañón, Universidad Europea, Universidad Complutense, Madrid, Spain.
- Hospital Clinic, Barcelona, Spain.
- Hospital Universitario Ramón y Cajal, Madrid, Spain.
ORCID-Profile: Domingo A Pascual-Figal, Eduard Solé-González
Förderung
- Roche España
Zitieren
APA
Pascual-Figal, D. A., Hernández-Vicente, A., Pastor-Pérez, F., Martínez-Sellés, M., Solé-González, E., Alvarez-García, J., García-Pavía, P., Varela-Román, A., Sánchez, P. L., Delgado, J. F., Noguera-Velasco, J. A., Bayes-Genis, A., & NICE study investigators (2024). N-Terminal Pro-B-Type Natriuretic Peptide Post-Discharge Monitoring in the Management of Patients with Heart Failure and Preserved Ejection Fraction – A Randomized Trial: The NICE Study. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3222
Vancouver
Pascual-Figal DA, Hernández-Vicente A, Pastor-Pérez F, Martínez-Sellés M, Solé-González E, Alvarez-García J, et al. N-Terminal Pro-B-Type Natriuretic Peptide Post-Discharge Monitoring in the Management of Patients with Heart Failure and Preserved Ejection Fraction – A Randomized Trial: The NICE Study. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3222
BibTeX
@article{PascualFigal2024,
author = {Pascual-Figal, Domingo A and Hernández-Vicente, Alvaro and Pastor-Pérez, Francisco and Martínez-Sellés, Manuel and Solé-González, Eduard and Alvarez-García, Jesús and García-Pavía, Pablo and Varela-Román, Alfonso and Sánchez, Pedro Luis and Delgado, Juan F and Noguera-Velasco, Jose A and Bayes-Genis, Antoni and NICE study investigators, NICE study investigators},
title = {N-Terminal Pro-B-Type Natriuretic Peptide Post-Discharge Monitoring in the Management of Patients with Heart Failure and Preserved Ejection Fraction – A Randomized Trial: The NICE Study},
journal = {European Journal of Heart Failure},
year = {2024},
doi = {10.1002/ejhf.3222}
}
EUVIMED